ACER Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 lapkr. 2023 @ 22:59):

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases...

Stats
Šios dienos apimtis	574 675
Vidutinė apimtis	2.39M
Rinkos kapitalizacija	16.15M
EPS	$-0.600 ( 2024-03-25 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.342
ATR14	$0.0570 (8.64%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-17	Aselage Steve	Sell	483 741	Common Stock, $0.0001 par value per share
2023-11-17	Dunn John Michael	Sell	27 380	Common Stock, $0.0001 par value per share
2023-11-17	Joseph Donald	Sell	14 285	Common Stock, $0.0001 par value per share
2023-11-17	Schelling Chris	Sell	2 712 529	Common Stock, $0.0001 par value per share
2023-11-17	Palmin Harry S	Sell	125 000	Common Stock, $0.0001 par value per share

INSIDER POWER
-68.02
Last 96 transactions
Buy: 5 870 002 \| Sell: 3 622 222

Tūris Koreliacija

Ilgas: 0.50 (weak)

Trumpas: -0.98 (very strong negative)

Signal:(30.163) Neutral

Acer Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BIRD	0.965
CNTY	0.965
COLB	0.964
FTXO	0.963
KBWB	0.962
AIRG	0.961
FITB	0.961
CPTN	0.96
PRCH	0.958
EVLO	0.957

10 Labiausiai neigiamai susiję koreliacijos
OPNT	-0.949
DVCR	-0.944
DSEY	-0.941
AMYT	-0.935
CCRC	-0.933
SUMO	-0.93
DAKT	-0.919
SGEN	-0.918
BTBD	-0.917
PPYAU	-0.913

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Acer Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.36
( neutral )

0.41
( neutral )

0.00
( neutral )

0.25
( neutral )

-0.86
( strong negative )

0.00
( neutral )

Acer Therapeutics Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.770

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.770

FY	2021
Pajamos:	$1.26M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.080

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

Acer Therapeutics Inc

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.